Appendix Y – Critical Data Fields
The following data fields are deemed crucial to outcomes based research.

Field	FormsNet [™] Forms
Disease	2400, 2000, 2010-2045, 2100, 2110-
	2145, 2450
Disease stage	2400, 2010-2045, 2055
Diagnosis date	2010-2045, 2055
Patient birth date	2400, 2000
Patient CMV status	2400, 2000
Patient race	2400, 2000
Karnofsky score at transplant	2400, 2000
Infusion date	All Forms
Preparative regimen drugs indicator	2400, 2000
Cy, Bu, Ara-c, VP-16, other drugs	2400, 2000
Radiation indicator	2400, 2000
Total body irradiation indicator	2400, 2000
TBI dose	2400, 2000
Total body irradiation dose unit of measure	2400, 2000
Were pharmacokinetics performed to determine	2000
preparative regimen drug dosing?	
Busulfan, Cyclophosphamide, Other drugs	2000
Non-myeloablative/reduced intensity (allo only)	2400, 2000
Ex-vivo graft manipulation	2400
Disease assessment at diagnosis	2028, 2029, 2030
Date of most recent assessment for disease	2010-2027
status prior to the preparative regimen:	
Disease status pre-HSCT	2400, 2010-2027
Cytogenetic remission pre-HSCT	2400, 2010, 2011, 2012
Molecular remission pre-HSCT	2400, 2010, 2011, 2012
Serological evidence of Hepatitis B pre-HSCT	2047
Transplant type	All forms
Product type	All forms
Donor or recipient tested for IDMs?	2004
Person for whom HLA typing is being done:	2005
Height/weight prior to the initiation of	2000
preparative regimen	2400 2000
Consent forms Contact date/date of follow-up	2400, 2000 2100, 2200, 2300, 2450
Engraftment indicator	2100, 2200, 2300, 2450
Engraftment date	2100, 2200, 2300, 2450
Subsequent decline date	2100, 2200, 2300, 2430
Second infusion indicator	2100, 2200, 2300
Second infusion date	2100, 2200, 2300, 2450
Acute GVHD Indicator (allo only)	2100, 2200, 2300
Date of onset (allo only)	2100, 2200, 2300
Skin involvement (allo only)	2100, 2200, 2300
Intestinal tract (allo only)	2100, 2200, 2300
Liver (allo only)	2100, 2200, 2300
(wii viii)	_ 100,

National Marrow Donor Program® and The Medical College of Wisconsin

Document Title: CIBMTR Forms Manual: Appendix Y: Critical Fields

Document Number: A00621 version 1

Page 1 of 2

AGVHD other clinical organ involvement	2100, 2200, 2300
Maximum grade (allo only)	2100, 2200, 2300, 2450
Chronic GVHD indicator (allo only)	2100, 2200, 2300
Date of onset (allo only)	2100, 2200, 2300, 2450
Onset code (allo only)	2100, 2200, 2300
Maximum grade (allo only)	2100, 2200, 2300, 2450
Organ involvement	2100, 2200, 2300
Present on date of contact	2100, 2200
Continued from previous reporting period	2450
Immunosuppressant therapy indicator	2100, 2200, 2300
New malignancy, lymphoproliferative or	2100, 2200, 2300, 2450
myeloproliferative disorder	
Disease status post-HSCT	2110-2127
Disease status assessment date	2110-2127
CR assessment post-HSCT	2110, 2111, 2112, 2450
Assessment date	2110, 2111, 2112, 2450
Best response to HSCT	2113-2127, 2140, 2141, 2142
Date of best response	2113-2127, 2140, 2141, 2142
Relapse or progression post-HSCT data fields	2110-2116, 2119-2127, 2140-2143,
	2450
Method of latest disease assessment data fields	2450
Karnofsky score post transplant	2100, 2200, 2300
Death indicator	2100, 2200, 2300, 2450
Date of death	2450, 2900
Cause of death	2450, 2900
Autopsy performed	2900
Product volume	2006
Product manipulation	2006
Product hematology & differential	2006
Mononuclear & CD34+ cell counts	2006
Time product infusion initiated	2006
Adverse event indicator	2006
CBU secondary containers intact indicator	2006
CBU frozen on arrival indicator	2006
CBU storage prior to thawing indicator	2006
CBU primary container intact indicator	2006